Quantcast
Channel: clinical trials – adam g. dunn
Viewing all articles
Browse latest Browse all 7

Another approved drug may leave the market

$
0
0
Bevacizumab Treatment for Solid Tumors, February 2, 2011, Hayes 305 (5): 506 — JAMA Avastin is a really expensive (think 50K a year) and dangerous (people die more often) drug that has been shown to have marginal positive effects on the progression of cancer for some patients. It is a very difficult question to weigh […]

Viewing all articles
Browse latest Browse all 7

Trending Articles